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Abstract: Context. Calcifediol has been proposed as a potential treatment for COVID-19 patients.
Objective: To compare the administration or not of oral calcifediol on mortality risk of patients
hospitalized because of COVID-19. Design: Retrospective, multicenter, open, non-randomized cohort
study. Settings: Hospitalized care. Patients: Patients with laboratory-confirmed COVID-19 between
5 February and 5 May 2020 in five hospitals in the South of Spain. Intervention: Patients received
calcifediol (25-hydroxyvitamin D3) treatment (0.266 mg/capsule, 2 capsules on entry and then one
capsule on day 3, 7, 14, 21, and 28) or not. Main Outcome Measure: In-hospital mortality during
the first 30 days after admission. Results: A total of 537 patients were hospitalized with COVID-19
(317 males (59%), median age, 70 years), and 79 (14.7%) received calcifediol treatment. Overall,
in-hospital mortality during the first 30 days was 17.5%. The OR of death for patients receiving
calcifediol (mortality rate of 5%) was 0.22 (95% CI, 0.08 to 0.61) compared to patients not receiving
such treatment (mortality rate of 20%; p < 0.01). Patients who received calcifediol after admission
were more likely than those not receiving treatment to have comorbidity and a lower rate of CURB-65
score for pneumonia severity ≥ 3 (one point for each of confusion, urea > 7 mmol/L, respiratory rate
≥ 30/min, systolic blood pressure < 90 mm Hg or diastolic blood pressure ≤ 60 mm Hg, and age
≥ 65 years), acute respiratory distress syndrome (moderate or severe), c-reactive protein, chronic
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kidney disease, and blood urea nitrogen. In a multivariable logistic regression model, adjusting
for confounders, there were significant differences in mortality for patients receiving calcifediol
compared with patients not receiving it (OR = 0.16 (95% CI 0.03 to 0.80). Conclusion: Among
patients hospitalized with COVID-19, treatment with calcifediol, compared with those not receiving
calcifediol, was significantly associated with lower in-hospital mortality during the first 30 days. The
observational design and sample size may limit the interpretation of these findings.
Keywords: COVID-19; calcifediol; SARS-CoV-2; COVID-19 drug treatment; vitamin D
1. Introduction
One of the most critical challenges facing contemporary medicine and public health
systems in the world has emerged from the 2019 coronavirus (COVID-19) pandemic [1].
The severity of a SARS-CoV-2 infection can range from asymptomatic or mild respiratory
symptoms to the development of respiratory failure, multiorgan failure, and death [2].
On 31 January 2020, the World Health Organization (WHO) announced that COVID-19
was labelled a Public Health Emergency of International Importance (PHEIC), and by
18 April 2021, it had affected over 141,334,774 confirmed cases with 3,024,317 deaths re-
ported globally [3]. However, there are still many unclear issues related to transmission,
infection, and treatment [1]. Since the beginning of the pandemic, intense pressure has
been put on clinicians and researchers to provide advanced treatments to save lives. How-
ever, the pathophysiology of severe COVID-19 is very complex. It is a potentially lethal
combination of immunopathogenic and immunoprotective responses in a prothrombotic
environment [4]. Unfortunately, no single mechanism or pathway discovered so far ex-
plains the entire pathophysiology. The problem is that there were only a few successful
therapies available, and still fewer have demonstrated efficacy compared to no treatment
in clinical trials [1]. It has and still is challenging to treat patients with coronavirus 2019
(COVID-19). Specialists face distressing emergencies in the intensive care unit where, at the
start of the pandemic, almost 20% of the hospitalized patients (with COVID-19) developed
Acute Respiratory Distress Syndrome (ARDS) and, despite recent advances in mechanical
ventilation and supporting treatment methods, about 65% of patients with ARDS died [5],
explaining why 25% of critically ill patients with severe COVID-19 died in the first outbreak
of the pandemic [6].
At the beginning of the pandemic, in the absence of specific COVID-19-causal treat-
ments clearly effective on mortality, several approved or investigational drugs with in vitro
activity against SARS-CoV-2 replication, including antiviral drugs such as lopinavir-
ritonavir, remdesivir, hydroxychloroquine, anti-parasitic ivermectin, and different im-
munomodulatory medications, were proposed as potentially useful [7]. However, the
WHO [8] has generated a strong recommendation against the use of hydroxychloro-
quine/chloroquine or lopinavir/ritonavir for treatment of COVID-19 of any severity,
restricting the use of ivermectin only to clinical trials. For remdesivir, effective in re-
ducing recovery time in adults hospitalized with COVID-19 [9], the WHO has established
a conditional recommendation against administering remdesivir in addition to usual care;
however, for dexamethasone or other corticosteroids, which are the only therapies that
have been shown to reduce mortality so far in patients with severe disease requiring
mechanical ventilation of high-flow oxygen [10], the WHO maintains a strong recommen-
dation for the use of systemic corticosteroids for severe or critically ill COVID-19 patients,
with a conditional recommendation against their use in patients with mild/moderate
COVID-19. Recently, the FDA has approved by Emergency Use Authorization baricitinib in
combination with remdesivir in patients requiring invasive mechanical ventilation or extra-
corporeal membrane oxygenation [11] as well as the neutralizing antibody bamlanivimab
(LY-CoV555) [12].
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Moreover, due to the absence of a specific treatment for ARDS, its management con-
sists of general supportive care required for all critically ill hospitalized patients (prevention
of blood clots, infection control, early nutritional assistance, and stress ulcer prophylaxis)
as well as the use of ventilation and oxygen therapy [13,14]. In this respect, it has been sug-
gested that the vitamin D endocrine system (VDES), by its extra-skeletal actions especially
on the lung and the immune system, is a facilitator of immunocompetence with respect to
both innate and adaptive immunity [13,15–18].
In this context, the stimulation of the vitamin D receptor (VDR) of the VDES has been
proposed to reduce acute respiratory distress syndrome (ARDS), cardiac and coagulopathy
risk, and possibly death rates in patients with COVID-19 [15–17,19,20]. Supported by this
rationale, some clinical trials and studies of various types are currently underway to test
the possible benefit of using oral cholecalciferol (vitamin D3) or calcifediol (also known as
25-hydroxyvitamin D3) on patients with COVID-19 [17].
Cholecalciferol (or vitamin D3), obtained through cutaneous synthesis under UV-B
light and in small amounts from the diet, is the threshold nutrient of the vitamin D en-
docrine system (VDES). Transported by vitamin D-binding protein (DBP), it is converted
to 25-hydroxyvitamin D3 (25OHD) or calcifediol in the liver, primarily through the ac-
tion of 25 hydroxylase. Levels of 25OHD are used by health authorities and scientific
societies in America and Europe to establish the status of normality, the definition of
vitamin D deficiency, and the degrees of insufficiency of the same, upon which to establish
dietary reference intake values for vitamin D as well as the control of vitamin D deficiency,
insufficiency, or excess in the population [21].
Calcifediol is a prohormone of VDES that serves as a substrate for the synthesis of
1,25(OH)2D or calcitriol via 1-hydroxylase (CYP2721B) in the kidney and multiple body
cells. Calcitriol functions as a hormone and binds at nuclear level to the vitamin D receptor
(VDR) with high affinity, controlling the expression of many genes with a wide range of
functional activities [13].
By its relative potency and pharmacokinetic characteristics, when compared to chole-
calciferol, oral calcifediol causes a faster increase in 25OHD serum levels [22,23].
The aim of our study was to compare the administration of oral calcifediol in conjunc-
tion with best available therapy versus best available therapy only and clinical outcomes
among hospital in-patients diagnosed with COVID-19.
2. Materials and Methods
Calcifediol was approved by the Ethics Committee for the treatment of COVID-
19 in the Reina Sofía University Hospital, Córdoba, Spain (EU) (Act-29/2020). Physi-
cians formally informed patients or legal representatives about the calcifediol treatment
and recorded their consent in the hospital’s electronic medical record. The retrospective
data collection and analysis of the patients included in this study were approved by the
Málaga provincial research ethics committee (protocol code “Registro-SEMI-COVID-19”,
27 March 2020).
2.1. Study Design, Sites, and Participants
This retrospective, multicenter cohort study included 537 patients with a clinical
picture of acute respiratory infection by COVID-19, radiographic signs of viral pneumonia,
and positive SARS-CoV-2 polymerase chain reaction, admitted between 5 February and 5
May 2020 in 5 public health system hospitals in the South of Spain in the regions of Córdoba,
Málaga, and Jaén (Hospital Universitario Reina Sofia, Córdoba; Hospital Universitario
Regional, Málaga; Hospital Costa del Sol, Marbella; Hospital de Montilla; and Hospital
Alto Guadalquivir, Andújar). The study included all sequentially hospitalized patients
excluding 76 subjects already reported as part of the randomized pilot study previously
reported of COVID-19 patients conducted in Hospital Universitario Reina Sofia [20]. The
pharmacy and ethics committee authorized this hospital to use calcifediol treatment (as
applied in the pilot trial) at the specialist’s discretion. No standardized criteria were used to
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indicate the use of calcifediol treatment. The different healthcare professionals involved in
the treatment of the patients described in this study, composed of multidisciplinary teams,
indicated at their discretion and under their clinical reasoning the use of the different
therapeutic options used to address the infection. In the other hospitals, it was not included
as it was not authorized by their respective committees. Medical records were analyzed for
medications, pre-existing diseases, clinical measures on admission, outcomes, and adverse
effects. Flow-chart of the study is shown in Figure 1.
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Figure 1. Flow chart of patients included in the stu y. Ce ter A, Hospital Universitario Reina
Sofia (Córdoba, Spain); Center B, Hospital Costa del Sol (Marbella, Spain); Center C, Hospital Alto
Gualdalquivir (Andújar, Spain); Center D, Hospital Montilla (Córdoba, Spain); Center E, Hospital
Universitario Regional (Málaga, Spain).
2.2. Laboratory Analysis and Respiratory Function Test
Clinical specimens required for SARS-CoV-2 diagnostic procedures were obtained on
admission by nasopharyngeal exudate sampling following WHO guidelines and recom-
mendations. RNA extraction and real-time RT-PCR (rtRT-PCR) were performed at the local
Central Microbiology Laboratory (Code 202 MagCore® Viral Nucleic Acid Extraction Kit by
Kapa Biosystems Inc. (Wilmington, MA, USA), Allplex™ 2019-nCoV Assay by Seegene Inc.
(Seoul, Korea), or VIASURE SARS-CoV-2 real-time PCR D te tion Kit by CerTest Biotec
S.L. (Zaragoza, Spain)).
After blood sample collection, we determined a complete blood count using flow
cytometry (ADVIA 2120i, Siemens Healthineers, Erlangen, Germany), coagulation study
including d-dimer (coagulation and immunoturbidimetric assay on ACL TOP 700, Instru-
mentation Laboratory/Werfen), and others parameters related to renal and liver function,
lactate dehydrogenase (spectrophotometric assay on Advia chemistry 2400 XPT, Siemens
Healthineers, Erlangen, Germany), ferritin, C-reactive protein (CRP) (immunoturbidimetric
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assay on Advia chemistry 2400 XPT, Siemens Healthineers, Erlangen, Germany), and IL-6
(chemiluminescent immunoassay on Advia Centaur XPT, Siemens Healthineers, Erlangen,
Germany). O2 saturation (SaO2) and chest radiography were determined in all patients on
admission. An expert team of thoracic radiologists evaluated all radiographic evidence.
The Berlin definition was used to define ARDS [24]. The CURB-65 score for severity of
pneumonia (CURB-65) was calculated according to its international definition [25].
2.3. Procedures
According to hospital protocol, all hospitalized patients received the best available
treatment for SARS-CoV-2 infection and standard care for pre-existing comorbidities. In
addition, patients from the Hospital Universitario Reina Sofia (n = 132) were categorized
into 2 treatment groups based on having received from admission: (1) oral calcifediol
(25-hydroxyvitamin D3) in soft gelatin capsules (0.532 mg), then oral calcifediol (0.266 mg)
on day 3 and 7, and then weekly until discharge or ICU admission following the posol-
ogy of the pilot study from Hospital Universitario Reina Sofia, Córdoba [20] or (2) no
treatment with calcifediol. All patients or legal representatives gave their informed con-
sent before initiating treatment with calcifediol, according to the protocol approved by
the Pharmacy Committee and by the Ethics Committee for the Treatment of COVID-19
of the Hospital Universitario Reina Sofía, Córdoba, Spain. Patients from the other four
centers did not receive treatment with calcifediol, and they were included in the analysis
as not-treated patients.
2.4. Outcome
We measured the rate of in-hospital deaths in the first 30 days after admission as
the primary outcome. Our hypothesis in this retrospective study was that treatment with
calcifediol would reduce the risk of death.
2.5. Statistical Analysis
To assess the association between treatment groups and clinical variables measured,
χ2 test or Fisher’s exact test were used for categorical variables and Student’s t-test or
Kruskal–Wallis test for continuous ones. By multivariable logistic regressions, we cal-
culated the odds ratio of mortality risk by group of treatment, also adjusting by several
potential confounders (date of hospitalization before or after approval of calcifediol treat-
ment in Center A, age, gender, center, diabetes, chronic lung disease, smoking status,
hypertension, coronary artery disease, cerebrovascular disease, congestive heart failure, O2
saturation at admission, chronic kidney disease, chronic liver disease, dementia, cancer, use
of angiotensin-converting enzyme inhibitor (ACEi) or angiotensin II receptor antagonists
(ARBs), ratio neutrophil/lymphocytes, blood urea nitrogen, use of systemic corticosteroids
during hospitalization, and CURB-65 ≥ 3 and rate or ARDS moderate or severe as a mark-
ers of severity of the disease at admission). A multivariable logistic regression model
also including antimicrobial, immunomodulatory, and anticoagulant therapies used dur-
ing the hospitalization period of patients were calculated. Analyses were completed in
IBM® SPSS® Statistics for Macintosh version 20 (Release 20.0.0, Armonk, NY, USA). We
considered statistically significant results p-values < 0.05, and all tests were one-sided.
3. Results
A total of 537 patients with COVID-19 were admitted in five hospitals in the regions of
Córdoba, Málaga, and Jaén in the south of Spain between 14 February and 5 May 2020 and
were included in the analysis. Of these patients, 79 (14.7%) received calcifediol treatment,
and 458 (85.3%) did not (Figure 1).
The characteristics of patients at admission according to the group of treatment are
shown in Table 1. The non-calcifediol-treated group included more patients with chronic
kidney disease and without significant differences in age, gender, smoking status, diabetes,
hypertension, cerebrovascular disease, chronic obstructive lung disease, cancer, heart
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failure, coronary artery disease, or dementia. However, the supplemented groups had a
higher ratio of any comorbidity than the non-supplemented group. Non-supplemented
patients had lower rate of O2 saturation at admission (93 ± 6 vs. 95 ± 4), higher levels of
CRP, higher blood urea nitrogen, and higher rates of CURB65 ≥ 3 and ARDS (moderate
or severe) at admission without significative differences in neutrophil-to-lymphocyte
ratio, LDH, D-dimer, ferritin, or rate of systemic corticosteroids use. The rate of ARDS
(moderate or severe) at baseline in the untreated groups was 25% vs. 10% in patients
that were treated with calcifediol, and no statistical differences were found in the rate
of orotracheal intubation during hospitalization (6 vs. 4, p = 0.4). Only four patients
developed disseminated intravascular coagulation (DIC), with all of them in the untreated
group. Other medications dispensed are summarized in Table S1.
Table 1. Baseline characteristics of patients treated or not with calcifediol, days of hospitalization, and mortality after
30 days of follow-up.
Not Treated (n = 458) Treated (n = 79) p-Value
Age 67 ± 16 69 ± 15 0.23
Male (%) 60 53 0.15
Current smokers (%) e 5 3 0.26
CURB-65 ≥ 3 (%) 21 8 <0.01
ARDS moderate or severe (%) 25 10 <0.01
Any comorbidity (%) 68 87 <0.01
Diabetes (%) 20 20 0.5
Hypertension (%) 56 58 0.4
Cerebrovascular disease (%) 7 6 0.53
COPD (%) 8 3 0.06
Heart failure (%) 9 5 0.16
Chronic kidney disease (%) 8 1 0.02
Cancer (%) 5 4 0.23
Coronary heart disease (%) 12 9 0.29
Dementia (%) 8 8 0.60
ACEi/ARBs (%) 48 39 0.13
SaO2 at admission 93 ± 6 95 ± 4 0.03
CRP a 130 ± 100 100 ± 80 0.04
Lymphocytes 1150 ± 820 970 ± 480 0.05
Neutrophil-to-lymphocyte ratio 7 ± 7 6 ± 5 0.66
LDH b 340 ± 170 330 ± 150 0.50
D-dimer c 2500 ± 7200 1900 ± 5000 0.48
Ferritin d 950 ± 1210 650 ± 680 0.07
Blood urea nitrogen 22 ± 19 16 ± 15 0.01
Systemic corticosteroids (%) 45 38 0.15
Orotracheal intubation, n (%) 26 (6) 3 (4) 0.36
Mortality, n (%) 90 (20) 4 (5) <0.001
a. CRP n = 346; b. LDH n = 480; c. D-dimer n = 480; d. Ferritin n = 296; e. Smoking status n = 508. Results are mean ± SD or % as indicated.
p-values were calculated with Fisher’s exact test for categorical variables (Exact Sig. 1-sided) and the Student’s t-test or Kruskal–Wallis test
for continuous ones. Abbreviations: ACEi/ARBs, angiotensin-converting enzyme inhibitor or angiotensin II receptor antagonists; ARDS,
acute respiratory distress syndrome; COPD, chronic obstructive pulmonary disease; CRP, c-reactive protein; CURB-65, CURB-65 score for
pneumonia severity; LDH, lactate dehydrogenase; SaO2, arterial oxygen saturation.
Baseline characteristics of patients according to center of recruitment are presented in
Supplementary Table S2.
Primary Outcome
Overall, in-hospital mortality during the first 30 days was 17.5%. Cumulative distri-
bution of in-hospital death according to treatment group is shown in Figure 2. Patients
supplemented with calcifediol had lower risk of death during hospitalization (5% vs. 20%,
p-value < 0.01).
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The OR of death for patients receiving calcifediol was 0.22 (95% CI, 0.08–0.61),
p-value < 0.01, compared to p tients not receiving suppl mentation.
In multivariate analysis, including potential confounders into the logistic regression
model, calcifediol treatment remained statistically significant (OR = 0.16, 95%CI = 0.03–0.80)
with age, center, CURB-65 ≥ 3, ARDS (moderate or severe) at admission, neutrophil/lymp-
hocytes ratio, prior history of cereb ova cular disease, chr nic obstructive pulmonary
disease, and cancer as other independent predictors of mortality (Table 2).
The multivariable logistic model developed also included in analyses antimicrobial,
immunomodulatory, and anticoagulant therapies used during the hospitalization period of
patients, and OR of death for patients treated with calcifediol was 0.2 (95% CI, 0.04–0.9,
p-value = 0.04) compared to patients not receiving that treatment.
The number of patients who died among the 53 control patients in center A and
their distribution of confounders versus patients treated with calcifediol are showed in
Supplementary Table S3. The statistically significant variables of multivariable logistic
regression model for risk of in-hospital death in Center A were calcifediol treatment
(OR = 0.01, 95%CI = 0.001–0.5) and ratio NL (OR = 1.6, 95%CI = 1.1–2.3) (Supplementary
Table S4).
Even after selecting those patients over 65 years of age and with oxygen saturation
levels at admission <96%, treatment with calcifediol was associated with a lower risk of
mortality (OR 0.06, 95%CI = 0.04–0.8) (Supplementary Table S5).
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Table 2. Statistically significant variables of multivariable logistic regression model for risk of
in-hospital death.
OR 95%CI p-Value
Calcifediol treatment 0.16 0.03–0.80 0.02
Age 1.05 1.01–1.09 0.008
ARDS (moderate or severe) 44 17–115 <0.001
CURB-65 ≥ 3 2.8 1.20–6.7 0.01
Cerebrovascular disease 3.5 1.03–11.6 0.045
COPD 9.2 2.5–34 0.01
Cancer 5.2 1.81–15 0.002
Ratio N/L 1.06 1.00–1.12 0.047
Center
Center A 1 (Ref.) 1 (Ref.)
Center B 0.25 0.06–1.01 0.052
Center C 0.26 0.06–1.10 0.07
Center D 0.70 0.01–0.46 0.006
Center E 0.31 0.09–0.99 0.048
Odd ratios (OR) and 95% confidence intervals (95%CI) have been calculated with multivariable logistic regression
adjusted for date of hospitalization before or after approval of calcifediol treatment in Center A, age, gender,
center, diabetes, chronic lung disease, smoking status, hypertension, coronary artery disease, cerebrovascular
disease, congestive heart failure, O2 saturation at admission, chronic kidney disease, chronic liver disease,
dementia, cancer, use of angiotensin-converting enzyme inhibitor (ACEi) or angiotensin II receptor antagonists
(ARBs), ratio neutrophil/lymphocytes, blood urea nitrogen, use of systemic corticosteroids during hospitalization,
CURB-65 ≥ 3, ARDS moderate or severe, and use of calcifediol. Abbreviations: ARDS, acute respiratory distress
syndrome; COPD, chronic obstructive lung disease; CURB-65, CURB-65 score for pneumonia severity; Ratio N/L,
ratio neutrophil/lymphocytes; Center A, Hospital Universitario Reina Sofia (Córdoba, Spain); Center B, Hospital
Costa del Sol (Marbella, Spain); Center C, Hospital Alto Gualdalquivir (Andújar, Spain); Center D, Hospital
Montilla (Córdoba, Spain); Center E, Hospital Universitario Regional (Málaga, Spain).
4. Discussion
In this multicenter observational study of 537 COVID-19 patients, those who received
calcifediol had a lower mortality rate during the first 30 days of hospitalization compared
to patients not receiving this treatment.
This was a retrospective, observational, non-randomized study, and therefore it is
no surprise that the two groups had different baseline characteristics. The treated group
had a higher overall risk of comorbidity, whereas the non-supplemented group had lower
values of O2 saturation at admission, higher CURB-65 score and higher rate of ARDS
moderate or severe, higher levels of inflammatory markers such as CRP, and a higher
frequency of kidney failure. Also, in the center where the treatment under study was
administered, untreated patients were older, had worse prognostic markers, a higher
percentage of comorbidities, dementia, or severity at the time of admission compared to
those who received treatment under clinical criteria. However, the protective effect of
calcifediol remained significant after adjustment for multiple confounder factors related to
severity disease even after selecting those subjects who were older (≥65 years) and had
worse oxygen saturation levels at admission (<96%).
Previously, our group reported in a pilot study of 76 consecutive patients hospital-
ized with COVID-19 infection that treatment with calcifediol decreased the need for ICU
treatment or respiratory assistance [20]. In the present study, we report a lower in-hospital
mortality rate during the first 30 days of hospitalization without statistical differences in
the use of orotracheal intubation. This last fact could be related to the lack of normalized
criteria for ICU admission between hospitals.
In terms of mechanisms, the modulatory ability of the vitamin D endocrine system
in host responses to SARS-CoV-2 has been previously identified in the literature, in both
the viremic and hyperinflammatory stages of COVID-19 infection [15–17]. Based on many
models, there is a clear argument that the VDES/VDR-signaling system can defend against
ARDS/acute lung damage by reducing cytokine and chemokine storm and protecting
the integrity of the pulmonary epithelial barrier [26–30]. Cells of the immune system and
cuboidal-alveolar epithelial coating cells type II (AECII) have the potential to produce
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1,25(OH)2D3 or calcitriol from calcifediol (25OHD3) [13]. Thus, this synthesized calcitriol
has the ability to modulate the expression of genes involved in the innate immune response,
resulting in the production of antimicrobial peptides (such as cathelicidin), defensins (beta-
defensine-2), and other components involved in pathogen intracellular destruction (such
as toll-like receptors co-receptor CD14) [31]. Furthermore, dsRNA increases the regulation
of 1-hydroxylase and sequentially synergizes with calcifediol and calcitriol to induce
cathelicidin in viral infection models [31]. Calcifediol and calcitriol were equipotent in the
in vivo animal model and (in vitro) on AECII cells [28,31] and the immune system [32,33],
suggesting that AECII cells and activated macrophages and lymphocytes were able to
actively convert calcifediol to calcitriol.
Vitamin D (25OHD) deficiency had been associated with severity and mortality of
patients with ARDS from various causes [34–36] and in SARS-CoV-2 infected patients.
Observational studies provide evidence that serum concentrations of 25OHD are inversely
correlated with the incidence or severity of COVID-19. Thus, ecological studies have
reported inverse correlations between historical mean concentrations of 25OHD levels and
the incidence and mortality of COVID-19 in European countries [19,37]. Lower concen-
trations of circulating 25OHD have also been reported to be associated with an increased
COVID-19 risk [38–41] and even with COVID-19 progression and severity [42–45]. Of
course, acute illness or inflammation may decrease serum concentrations of 25 OHD,
thereby influencing the interpretation of such observational data [46].
A recent meta-analysis of observational studies evaluating vitamin D levels in adult
and elderly subjects with COVID-19 found a pattern for a link between 25OHD deficiency
and COVID-19 health outcomes [47].
Additionally, the risk of severe COVID-19 infection and a 25OHD deficit overlaps with
other conditions such as aging, Black or Asian ethnicity, obesity, and poverty [48]. Serum
25OHD is frequently decreased during acute inflammatory diseases [49], and 25OHD is
thought to be a negative acute-phase reactant. Furthermore, to correct 25OHD deficiency
in seriously ill patients [50] or COVID-19 [51], higher than usual doses of cholecalciferol
are needed. For this reason, we used calcifediol as a treatment in hospitalized, severe
COVID patients. Calcifediol may have some advantages over cholecalciferol [52,53]. It
has a near-100 percent intestinal absorption rate and can quickly restore serum 25OHD
concentrations since it does not require hepatic 25-hydroxylation. This fact is crucial in
clinical circumstances where rapid restoration of serum 25OHD is desired but CYP2R1
expression is hampered, as it may be with COVID. CYP2R1 activity has been shown to be
impaired in several animal models [54] and has also been confirmed in COPD and asthma
patients [55].
The use of vitamin D3 in boluses administered during hospitalization for COVID-19
has not been shown to reduce the risk of death in studies carried out in Brazil (200,000
IU/5000 µg) [56] or in France (80,000 IU/2000 µg) [57]. However, the results of forthcoming,
well-designed RCTs will provide new and additional information on the relevance of
vitamin D in COVID-19 [58]. In a small, randomized, placebo-controlled trial from India
in 25-hydroxyvitamin D deficient (<20 ng/mL) COVID-19 patients, 62.5% of participants
treated with 60,000 IU/1500 µg/day of vitamin D3 for 7–14 days became negative for
SARS-CoV-2 within 21 days compared to only 20.8% in the untreated participants [51].
Moreover, regular supplementation with vitamin D3, at least in the elderly, in boluses
administered regularly during the year prior to diagnosis has shown a reduction in the risk
of death and clinical improvement in elderly patients with COVID-19 [59–61].
Unfortunately, serum levels of 25OHD were not available at baseline or during treat-
ment for the exceptional conditions of the first outbreak of COVID-19 [62,63]. According to
previous reports, in late winter and early spring, adults in the Córdoba area are relatively
25OHD deficient [64,65]. It is worth mentioning that deficiency (25OHD < 20 ng/mL) in
COVID-19 patients recently admitted to our hospitals has been repeatedly confirmed (data
not shown here); in addition, in subsequent studies at the Reina Sofia University Hospital
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of Córdoba, we verified increase of serum 25OHD above 30–40 ng/mL from the third day
of treatment in COVID-19 patients with the proposed calcifediol dosages.
The facts in the literature and the data in this manuscript appear to support principles
related to causality, such as strength of association, consistency, temporality, biological
gradient, plausibility, and coherence [66]. Our pilot study was the first experimental
verification trial reported [20] that additionally encouraged the present study. These two
studies together seem to indicate that Calcifediol treatment can reduce the severity of
the disease.
The strengths of this study include a cohort of patients hospitalized for COVID-19 in
five hospitals of different levels. However, this study has several limitations. First, this is
an observational study conducted on patients admitted during the first wave of patients
suffering COVID-19. Given that the administration of the treatment was not randomized,
and it was based on the clinical judgment of the professionals who attended these patients,
the adjustments described above have been made to try to control the possible effect on
final mortality of variables that showed statistical significance at the time of admission.
However, possible non-identifiable remaining confounding is possible. Secondly, since
the data were obtained from the databases of the electronic medical records, we were only
able to include those collected in these records for the present study. Data, such as the date
of symptom onset before admission, the patients’ body mass index, the presence of other
comorbidities, and the rate of development of acute kidney injury, among others, were
missing in most patients and could not be included. Finally, the post-discharge follow-up
events have not been taken into consideration due to lack of such information.
5. Conclusions
In conclusion, in this multicenter observational study, patients hospitalized with
COVID-19 and treated with calcifediol had lower in-hospital mortality during the first
30 days compared to those patients not supplemented. The observational design and sam-
ple size may limit the interpretation of these findings. Results from large-scale, randomized,
controlled trials of calcifediol, which are currently underway, are required for validation of
our observations.
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